CTX-2026

立即咨询

CTX-2026

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CTX-2026 是一种纯人源抗体，与CD277结合。CTX-2026 在卵巢肿瘤模型中显示抗肿瘤作用。CTX-2026 可用于癌症的研究。

生物活性

CTX-2026 is a fully human antibody that binds toCD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research ofcancer^[1].

体外研究
(In Vitro)

CTX-2026 (1 μg/mL; 12 h) redirects the cytotoxic activity of Vγ9Vδ2 T cells from multiple donors against BTN3A1⁺OVCAR3 cells or primary HGSOC cells^[1].
CTX-2026 (1 μg/mL; 6 d) shows a rescuing effect on nonablated CD45⁺T cells^[1].

体内研究
(In Vivo)

CTX-2026 (5 mg/kg; i.p. for 15 days every 3 days once) effects the tumor growth of NY-OVCAR3 tumor mice^[1].

Animal Model:	NSG mice with NY-OVCAR3 tumors^[1]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; 5 mg/kg 3 days for once; for 15 days
Result:	Effectively delayed malignant progression from nine different donors.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.